Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness of IDegLira in Chinese adults with type 2 diabetes
ChiCTR2500096325Phase 4Completed
- Sponsor
- Beijing Hospital
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Beijing Hospital. Primary endpoints: HbA1c and IDegLira dose. Started Jan 2025; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500096325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096325.